pargyline has been researched along with Diabetes Mellitus, Type 1 in 1 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral pargyline treatment protected transplanted beta cells in diabetic mice, thus leading to disease reversal." | 1.56 | Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes. ( Cai, EP; Hollister-Lock, J; Hou, S; Ishikawa, Y; Kiaf, B; Kissler, S; Leite, NC; Li, J; Melton, DA; Schiffer, CA; Yi, P; Yilmaz, NK; Zhang, W, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, EP | 1 |
| Ishikawa, Y | 1 |
| Zhang, W | 1 |
| Leite, NC | 1 |
| Li, J | 1 |
| Hou, S | 1 |
| Kiaf, B | 1 |
| Hollister-Lock, J | 1 |
| Yilmaz, NK | 1 |
| Schiffer, CA | 1 |
| Melton, DA | 1 |
| Kissler, S | 1 |
| Yi, P | 1 |
1 other study available for pargyline and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes.
Topics: Animals; Autoimmunity; CRISPR-Cas Systems; Diabetes Mellitus, Type 1; Endoplasmic Reticulum Stress; | 2020 |